- Home
- TCBS vs BYSI Comparison
TCBS vs BYSI Comparison
Compare TCBS & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCBS | BYSI |
|---|---|---|
| Founded | 1934 | 2010 |
| Country | United States | United States |
| Employees | 71 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 58.4M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TCBS | BYSI |
|---|---|---|
| Price | $17.50 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 822.0 | ★ 26.4K |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 327.27 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $56.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.70 | $0.99 |
| 52 Week High | $20.00 | $2.44 |
Technical Indicators
Market Signals| Indicator | TCBS | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 49.94 | 32.75 |
| Support Level | $15.86 | N/A |
| Resistance Level | $18.04 | $1.60 |
| Average True Range (ATR) | 0.21 | 0.11 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 43.25 | 23.96 |
Price Performance
Historical ComparisonAbout TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans, commercial real estate loans, and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer, and other.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.